• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » General Psychiatry

General Psychiatry
General Psychiatry RSS Feed RSS

Medications for Panic Disorder: An Update

March 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Alright, we can see you stifling that yawn, and we know what you’re thinking: “What on earth is there to say about treating panic disorder other than to use SSRIs or benzos?” Well, we’re up for the challenge!
Read More

Benzodiazepines are Bad. Or Are They?

March 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Nobody doubts that benzodiazepines (“benzos” or BZs) are effective in treating a wide range of anxiety disorders, but many believe that they are addictive, difficult and perhaps dangerous to stop taking, and that they cover up anxiety instead of truly treating it. Let’s take a closer look at each of the concerns.
Read More

The Role of GABA in Anxiety

March 1, 2006
Andrew Goddard, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Andrew Goddard, MD Professor of Psychiatry and Radiology; Director, Adult Outpatient Clinic and Anxiety Program, Indiana University Department of Psychiatry Dr. Goddard has disclosed that he was or is the recipient of research grants from Cephalon and Pfizer Pharmaceuticals; and was or is a consultant for AstraZeneca; and was or is a member of the speakers bureau of Pfizer Pharmaceuticals. The editors of The Carlat Psychiatry Report have closely reviewed the content of Dr. Goddard’s interview and have determined that there are no financial conflicts of interest regarding this educational activity. The author has disclosed that D-cycloserine, gabapentin, lamotrigine, pregabalin, and tiagabine have not been approved by the U.S. Food and Drug Administration for use in the treatment of anxiety. Please consult product labeling for the approved usage of these drugs.
Dr. Goddard, you’ve done a lot of neurobiological research in anxiety disorders. It’s a very complex area, but basically what goes on in patients’ brains when they have a panic attack?
Read More

Learning Objectives, Medication Treatment of Anxiety, TCPR, March 2006

March 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More

The CATIE Trial: The Story is in the Dosing

February 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Few clinical trials have ever generated as much buzz as the series of trials known as CATIE. CATIE stands for “Clinical Antipsychotic Trials of Intervention Effectiveness,” and is the only set of trials ever done comparing the major second-generation antipsychotics. And because CATIE is funded entirely by NIMH, its results are thought to be quite trustworthy (NEJM 2005;353:1209-1223).
Read More

Typical Antipsychotics: A Brief Review

February 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Those of us who completed residency anytime during the last 10 years were indoctrinated against the use of conventional neuroleptics because of their array of side effects, particularly extrapyramidal syndromes (EPS) and tardive dyskinesia (TD).
Read More

Background of the CATIE Trial

February 1, 2006
John Hsiao, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John Hsiao, MD Project Officer, National Institute of Mental Health Dr. Hsiao has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Dr. Hsiao, you were NIMH’s project officer for the CATIE trial. What was your goal when you came up with the idea for CATIE?
Read More

What is an “atypical”?

February 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Following the introduction of the first neuroleptics in the 1950s, pharmaceutical companies continued screening compounds for psychoactive properties. In 1959, at Wander Laboratories (ultimately purchased by Sandoz), researchers were surprised to discover a chemical similar to tricyclic antidepressants that had antipsychotic properties. They named it clozapine.
Read More

Learning Objectives, Antipsychotic Roundup 2006, TCPR, February 2006

February 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
After reading these articles, you should be able to…
Read More

Vagus Nerve Stimulation: Is the Evidence Convincing?

January 1, 2006
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Vagus nerve stimulation (VNS) is certainly new—but is it effective? It took the FDA a long time to make up its mind, but eventually it approved the treatment in May 2005. (For more details on why the FDA flip-flopped on the issue, see “FDA Approval of VNS,” this issue.) In this article, we scrutinize the two pivotal studies leading to approval.
Read More
Previous 1 2 … 153 154 155 156 157 158 159 160 161 … 176 177 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB7e_Print_App_Access.png

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

    The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2637648401.jpg
    General Psychiatry

    Psychopharm Secrets: Coming Off Meds

    There’s a hidden placebo response to watch for when patients stop meds on their own.
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.